albumin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
== Finite elasticity == The elastic behavior of objects that undergo finite deformations has been described using a number of models, such as Cauchy elastic material models, Hypoelastic material models, and Hyperelastic material models. The deformation gradient (F) is the primary deformation measure used in finite strain theory.
== Construction == The tablets were originally made of wood and wax, though only the wood was preserved and recoverable. A typical tablet would have been made of a thin piece of wood, 15–25 cm wide, with a rectangular depression carved into the centre. Warm beeswax, blackened by the addition of atramentum, would then be poured into the centre depression and allowed to cool. Once the wax had set, a metal stylus would be used to scratch letters into the wax, showing a lighter colour against the darker wax. These wax tablets could be recycled, in that the tablet could be heated (to approximately 50 °C), allowing the wax to soften and reform a smooth writing surface. The tablets were likely made from wood recycled from barrel staves, and often were made in diptych style, where two tablets were loosely linked and could fold together to close, like a book with only two pages, protecting the soft wax on the inside. Evidence suggests the tablets were made from staves due to the discovery of several staves and glazing objects at the site alongside the tablets. These staves are of the same type of wood (silver fir) as the tablets. However there were two ink leaf tablets inscribed with a pen that were discovered at the same site.
Selenium deficiency occurs when an organism lacks the required levels of selenium, a critical nutrient in many species. Deficiency, although relatively rare in healthy well-nourished individuals, can have significant negative results, affecting the health of the heart and the nervous system; contributing to depression, anxiety, and dementia; and interfering with reproduction and gestation.
Oliver Platt (born January 12, 1960) is an American actor known for his work on stage and screen. He has been nominated for five Primetime Emmys, a Golden Globe Award, two Screen Actors Guild Awards, and one Tony Award. Following his acting debut in the 1988 film Married to the Mob, Platt gained prominence for his roles in Working Girl (1988), Flatliners (1990), Beethoven (1992), Indecent Proposal, Benny & Joon, The Three Musketeers (all 1993), A Time to Kill (1996), The Impostors, Bulworth, Dr. Dolittle (all 1998), Lake Placid, Three to Tango, and Bicentennial Man (all 1999). His other notable credits include Gun Shy, Ready to Rumble (both 2000), Don't Say a Word (2001), Pieces of April (2003), Kinsey (2004), The Ice Harvest, Casanova (both 2005), Frost/Nixon (2008), Year One, 2012 (both 2009), Please Give, Love & Other Drugs (both 2010), and X-Men: First Class (2011). Platt is known for his work on television series such as The Big C (2010–2013), Fargo (2014) and The Good Wife (2015). He received a Screen Actors Guild Award nomination for his portrayal of George Steinbrenner in the ESPN miniseries The Bronx Is Burning (2007) as well as nominations for the Primetime Emmy for Outstanding Guest Actor for his roles in The West Wing (2001), Huff (2005; 2006), and Nip/Tuck (2008). He is known for his recurring role as Uncle Jimmy on Hulu's The Bear (2022–2026) and has played Dr. Daniel Charles on Chicago Med since 2015. On stage, Platt made his Broadway debut in the Conor McPherson play Shining City (2006) for which he was nominated for the Tony Award for Best Actor.
Sources: en.wikipedia.org
Aminothiazole (2-thiazolamine) (1) is condensed with 2-acetylbutyrolactone [517-23-7] (2) under DS-trap until the water has separated. Condensation of this β-keto lactone can be visualized to involve initial attack on the reactive butyrolactone by the primary nitrogen; cyclodehydration of that hypothetical intermediate 3 gives 6-(2-hydroxyethyl)-7-methyl-[1,3]thiazolo[3,2-a]pyrimidin-5-one, CID:82612453 (4). Halogenation of the terminal alcohol with phosphorus oxychloride then yields 6-(2-chloroethyl)- 7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one, [86488-00-8] (5). Alkylation with 4-(bis(4-fluorophenyl)methylene)piperidine, [58113-36-3] (6) would complete the synthesis of ritanserin (7).
The concept of Portal came from Narbacular Drop, a student project from the DigiPen Institute of Technology. The game included the aspects of placing portals on any flat surfaces and using them to maneuver around levels. Several Valve employees, attending a DigiPen career fair, saw Narbacular Drop and offered the entire team jobs at Valve almost immediately to help expand on their idea. Valve originally saw Portal as an experimental game to be included with its upcoming compilation, The Orange Box, alongside its release of Half-Life 2: Episode Two and Team Fortress 2. To give the game character, a minimal story, tied loosely with the Half-Life world, was written by Valve's Erik Wolpaw. He needed a character to guide the player through the game, coming onto a polite but humorous artificial intelligence, which would ultimately become the character of GLaDOS. Portal's release with The Orange Box received near-universal praise, with the standalone game earning an aggregate Metacritic rating of 90 out of 100. With success of the game, work on an expanded sequel began nearly immediately, expanding the development team from 8 to about 30-40 programmers. Initial ideas for Portal 2 retained the idea of solving puzzles through scientific concepts, but eliminating the use of portals altogether; these versions did not fare well with test audiences nor with Gabe Newell, Valve's president; these ideas were dropped though saved for potential reuse in a different game by Valve.
Thus, iodine-131 is increasingly less employed in small doses in medical use (especially in children), but increasingly is used only in large and maximal treatment doses, as a way of killing targeted tissues (i.e. therapeutic use). Iodine-131 can be "seen" by nuclear medicine imaging techniques (e.g., gamma cameras) whenever it is given for therapeutic use, since it is a strong emitter of gamma radiation. However, since the beta radiation causes tissue damage without contributing to any ability to see or "image" the isotope, other less-damaging radioisotopes of iodine such as iodine-123 (see isotopes of iodine) are preferred in situations when only imaging is wanted. The isotope 131I is still occasionally used for purely diagnostic (i.e., imaging) work, due to its low expense compared to other iodine radioisotopes. No increase in thyroid cancer has been seen from the small medical imaging doses of 131I. The low-cost availability of 131I, in turn, is due to the relative ease of creating 131I by neutron bombardment of natural tellurium in a nuclear reactor, then separating 131I out by various simple methods (i.e., heating to drive off the volatile iodine). By contrast, other iodine radioisotopes are usually created by far more expensive techniques, starting with cyclotron radiation of capsules of pressurized xenon gas. Iodine-131 is also one of the most commonly used gamma-emitting radioactive industrial tracer.
== San Diego Chargers == The nickname "Fearsome Foursome" was used to describe the early 1960s American Football League's San Diego Chargers' defensive front four. One report is the nickname was originally used for the Chargers line by the team's press agent Bob Burdick, in 1963. The Fearsome Foursome name, however, was used by at least the early 1962 season for the line consisting of right defensive end Ron Nery, left defensive end Earl Faison, left defensive tackle Bill Hudson and right defensive tackle Ernie Ladd. A November 1961 newspaper article about this same Chargers’ defensive line is entitled “Fearsome Foursome Averages 273”. The Chargers moved from Los Angeles to San Diego in 1961, Faison's and Ladd's rookie season. Faison and Ladd would be the core of the Chargers' Fearsome Foursome from 1961 to 1965. Contract disputes with the Chargers led to Faison and Ladd leaving the team in 1966, with Ladd playing the 1966 season for the Houston Oilers, and Faison playing in only three games for the Chargers before going to the Miami Dolphins. Faison was an AFL All-Star in his first five seasons with the Chargers (1961-65), and was All-AFL every year but 1962. He was the only defensive player to ever win the Associated Press (AP) and The Sporting News AFL Rookie of the Year during the AFL's existence (1960-69), and one of only two defensemen to win United Press International's (UPI) AFL Rookie of the Year. The 6 ft 9 in (2.06 m), 290 lb.
concentrated table salt is toxic to many slugs and snails). Bioaccumulation of chemically-prepared agricultural insecticides is a matter of concern for the many species, especially birds, which consume insects as a primary food source. Selective toxicity, controlled application, and controlled biodegradation are major challenges in herbicide and pesticide development and in chemical engineering generally, as all lifeforms on earth share an underlying biochemistry; organisms exceptional in their environmental resilience are classified as extremophiles, these for the most part exhibiting radically different susceptibilities.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.